IDEXX Laboratories, Inc. $IDXX Stock: Verdence Capital Advisors LLC Decreases Stake

Verdence Capital Advisors LLC decreased its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 22.6% during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 3,721 shares of the company’s stock after selling 1,086 shares during the quarter. Verdence Capital Advisors LLC’s holdings in IDEXX Laboratories were worth $1,943,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of IDXX. Bank of New York Mellon Corp bought a new position in IDEXX Laboratories in the 2nd quarter worth $628,223,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in IDEXX Laboratories by 4.6% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 911,489 shares of the company’s stock valued at $479,844,000 after acquiring an additional 39,700 shares during the period. Arrowstreet Capital Limited Partnership raised its holdings in IDEXX Laboratories by 52.4% during the first quarter. Arrowstreet Capital Limited Partnership now owns 838,839 shares of the company’s stock valued at $471,335,000 after acquiring an additional 288,471 shares during the period. Dimensional Fund Advisors LP raised its holdings in IDEXX Laboratories by 4.3% during the first quarter. Dimensional Fund Advisors LP now owns 573,332 shares of the company’s stock valued at $322,145,000 after acquiring an additional 23,582 shares during the period. Finally, Alyeska Investment Group L.P. lifted its position in shares of IDEXX Laboratories by 97.3% in the second quarter. Alyeska Investment Group L.P. now owns 401,082 shares of the company’s stock valued at $211,146,000 after acquiring an additional 197,808 shares in the last quarter. Institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Stock Performance

Shares of NASDAQ:IDXX opened at $561.25 on Wednesday. The firm has a fifty day moving average price of $533.69 and a 200 day moving average price of $576.39. IDEXX Laboratories, Inc. has a fifty-two week low of $500.61 and a fifty-two week high of $769.98. The firm has a market cap of $44.22 billion, a price-to-earnings ratio of 39.47 and a beta of 1.55.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Tuesday, August 4th. The company reported $4.27 earnings per share for the quarter, beating the consensus estimate of $3.94 by $0.33. The company had revenue of $1.22 billion for the quarter, compared to analysts’ expectations of $1.20 billion. The business’s revenue was up 9.7% on a year-over-year basis. During the same period in the previous year, the business posted $3.50 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. As a group, research analysts predict that IDEXX Laboratories, Inc. will post 14.81 earnings per share for the current year.

Analyst Ratings Changes

IDXX has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. dropped their price objective on IDEXX Laboratories from $775.00 to $750.00 and set an “overweight” rating for the company in a research note on Friday, October 16th. KeyCorp began coverage on IDEXX Laboratories in a research report on Monday, October 12th. They set a “sector weight” rating for the company. Jefferies Financial Group decreased their target price on IDEXX Laboratories from $795.00 to $705.00 and set a “buy” rating on the stock in a research note on Tuesday, October 20th. Leerink Partners lowered their price target on IDEXX Laboratories from $725.00 to $715.00 and set an “outperform” rating on the stock in a report on Monday, July 13th. Finally, Wall Street Zen downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Nine equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat, IDEXX Laboratories has an average rating of “Moderate Buy” and a consensus target price of $727.69.

Insider Buying and Selling

In other news, Director Lawrence D. Kingsley sold 2,203 shares of the firm’s stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $532.08, for a total transaction of $1,172,172.24. Following the completion of the transaction, the director owned 9,568 shares in the company, valued at $5,090,941.44. This trade represents a 18.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 0.79% of the stock is currently owned by insiders.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) develops and provides diagnostic, information technology, and related products and services for the animal health and water testing markets. The company primarily serves veterinary practices, helping them diagnose and monitor diseases through laboratory tests, in-clinic analyzers, software, and digital practice-management solutions.

IDEXX’s companion animal offerings include hematology, chemistry, urinalysis, immunodiagnostics, and imaging-related products, along with reference laboratory services and veterinary software.